ERBB2 and breast cancer: The strengths of this study include the large landmark N9831 randomized trial population of patients with HER2-positive breast cancer, randomized to chemotherapy ± trastuzumab treatment, using high-quality central and reference laboratories with standardized methods for FISH and RT-PCR assays [20, 21, 52, 62].